Pentadeca Arginate
Very early researchGet notified when the evidence changes.
The research is at the earliest stage – mostly cells in a lab dish. It is far too early to say much.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04
Also called PDA / PDA-157 / Pentadecapeptide arginate
A newer variant of BPC-157 with a changed salt form. Very little published research exists on it specifically.
Official status: Not nominated for 503A compounding · Checked 2026-08-04
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
Not approved and not on the compounding list. It was not part of the July 2026 review.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
No dosing information has been published in the research indexed here.
No studies indexed yet.
Spot an error? corrections@peptidesearch.org